Moderna to Present Promising Phase 1/2 Clinical and Safety Data for Cancer Antigen Therapy mRNA-4359 at ESMO 2025

Moderna Inc. (NASDAQ:MRNA) is one of the best high volume stocks to buy according to Wall Street analysts. On October 13, Moderna announced that promising clinical, safety, and translational data from its Phase 1/2 study evaluating the investigational immune-evasion targeted cancer antigen therapy/CAT mRNA-4359 would be presented at the 2025 European Society for Medical Oncology/ESMO Congress.

mRNA-4359 is an immune-evasion targeted CAT that encodes epitopes of two common immune escape pathways: PD-L1 and IDO1. Its dual mechanism of action is designed to elicit antigen-specific T-cell responses to both directly kill tumor cells expressing PD-L1 and IDO1, and deplete immunosuppressive cells in the tumor microenvironment, aiming to establish an immune-permissive state for sustained anti-tumor activity.

Moderna to Present Promising Phase 1/2 Clinical and Safety Data for Cancer Antigen Therapy mRNA-4359 at ESMO 2025

Across all evaluable patients, the therapy demonstrated an objective response rate of 24% and a disease control rate of 60%. It continues to be evaluated as a monotherapy and in combination with pembrolizumab in patients with advanced melanoma and non-small cell lung cancer/NSCLC.

Moderna Inc. (NASDAQ:MRNA) is a biotechnology company that provides messenger RNA medicines in the United States, Europe, and internationally.

While we acknowledge the potential of MRNA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRNA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.